Table 2.
Overall | Male | Female | ||||
Clinical stage (n/%) | ||||||
I-A | 3 | 2.4 | 1 | 1.5 | 2 | 3.4 |
I-B | 7 | 5.6 | 5 | 7.6 | 2 | 3.4 |
II-A | 28 | 22.4 | 12 | 18.2 | 16 | 27.1 |
II-B | 11 | 8.8 | 6 | 9.1 | 5 | 8.5 |
III-A | 5 | 4.0 | 4 | 6.1 | 1 | 1.7 |
III-B | 11 | 8.8 | 5 | 7.6 | 6 | 10.2 |
III-C | 12 | 9.6 | 7 | 10.6 | 5 | 8.5 |
IV | 48 | 38.4 | 26 | 39.4 | 22 | 37.3 |
Total | 125 | 100.0 | 66 | 100.0 | 59 | 100.0 |
Site of cancer (n/%) | ||||||
Right side | 30 | 21.4 | 14 | 18.9 | 16 | 24.2 |
Left side | 110 | 78.6 | 60 | 81.1 | 50 | 75.8 |
Total | 140 | 100.0 | 74 | 100.0 | 66 | 100.0 |
Histopathological grade (n/%) | ||||||
Well differentiated | 29 | 33.3 | 17 | 35.4 | 12 | 30.8 |
Moderately differentiated | 47 | 54.0 | 27 | 56.3 | 20 | 51.3 |
Poorly differentiated | 11 | 12.6 | 4 | 8.3 | 7 | 17.9 |
Total | 87 | 100.0 | 48 | 100.0 | 39 | 100.0 |